-
Cubans ready for Russian oil but some say not enough
-
Teen Suryavanshi shines as Rajasthan hammer Chennai in IPL
-
Stock market winners and losers one month into US-Israel war on Iran
-
Hodgson says surprise return to management is only for short-term
-
What could Trump achieve by threatening Iran's Kharg Island?
-
India declares victory over Maoist insurgency
-
Germany's Merz pushes return of Syrians as he hosts leader Sharaa
-
G7 ministers pledge 'necessary measures' to ensure stable energy market
-
Cardiff City lose compensation case over Emiliano Sala death
-
Several French far-right mayors take down EU flags
-
Air Canada CEO to retire after row over English-only condolence message
-
Oil rises on Trump's Iran threats, stocks take cue on talks
-
Syrian leader pledges to work with Germany on migration, recovery
-
AI agent future is coming, OpenClaw creator tells AFP
-
Cardiff lose 122 mn euro compensation case over Emiliano Sala death
-
Tuchel defends Rice and Saka after England withdrawals
-
G7 ministers tackle economic fallout of Mideast war
-
Tottenham close in on De Zerbi as next boss - reports
-
Kenya's former NY marathon champion Korir gets 5-year doping ban
-
Lukaku says 'could never turn back on Napoli' after treatment row
-
Syrian leader visits Germany to talk war, recovery, refugees
-
Renault says developing ground-based military drone
-
Iran hangs two 'political prisoners' from banned opposition: activists
-
Russia expels UK diplomat on spying allegations
-
Premier League fans back call to scrap VAR
-
Italy hoping to scale World Cup 'Everest' ahead of Bosnia play-off showdown
-
Japan's cherry blossom season dazzles locals and tourists
-
EU ups mackerel quotas to match UK despite overfishing concerns
-
Crude rises, stocks drop as Houthi attacks escalate Iran war
-
Australian Rules player banned for wiping blood on face of opponent
-
Sheep culls put pressure on Greek feta cheese production
-
One man, his dog, and ChatGPT: Australia's AI vaccine saga
-
Israel PM restores access after Latin Patriarch blocked from Holy Sepulchre
-
Israel strikes Tehran as Trump says Iran deal may be reached 'soon'
-
Italy chase World Cup spot as Kosovo bid to make debut
-
Myanmar paves way for junta chief to become civilian president
-
'Long live the shah': Iranian diaspora back war at Washington rally
-
Taiwan opposition leader accepts Xi's invitation to visit China
-
French masonic lodge at heart of murky murder trial
-
US military building 'massive complex' beneath White House ballroom project: Trump
-
IPL captain takes pop at Cricket Australia over record-buy Green
-
G7 ministers set to tackle financial fallout of Mideast war
-
Premier League fans feel the pinch from ticket price hikes
-
Australia to halve fuel tax in response to Middle East war
-
Crude surges, stocks dive as Houthi attacks escalate Iran war
-
Air China resumes flights to North Korea after 6-year pause
-
NBA-best Thunder beat Knicks as Boston seal playoff spot
-
Australian fugitive shot dead by police after seven-month manhunt
-
King Kimi, Max misery, Bearman smash: Japan GP talking points
-
Philippines oil refinery secures 2.5 mn barrels of Russian crude
Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
G.P.Martin--AT